SYDNEY--Pfizer Animal Health today announced the completion of the
previously-announced divestiture of certain Fort Dodge veterinary assets
in Australia to Virbac (Australia) Pty Limited. The financial terms of
the transaction were not disclosed.
Pfizer divested the assets in compliance with requirements imposed by
the ACCC in connection with Pfizer’s acquisition of Wyeth, including the
Fort Dodge business, by Pfizer in October 2009.
The assets acquired by Virbac consist of the Fort Dodge Australia
livestock business, including a range of livestock vaccines and the
Cydectin range of sheep and cattle parasiticides, along with a
biologicals manufacturing facility at Penrith, NSW.
“This transaction is the final divestiture of assets required by the
ACCC in relation to Pfizer Inc’s acquisition of Wyeth, including the
Fort Dodge Animal Health Business,” said Mr Mike Van Blommestein,
General Manager of Pfizer Animal Health in Australia.
“With the integration of Wyeth, including the Fort Dodge range of
veterinary products, Pfizer’s animal health business remains the world’s
leader in the discovery, development and manufacturing of veterinary
vaccines and medicines for livestock and companion animals,” added Mr.
Van Blommestein.
Pfizer Animal Health’s complete Australian portfolio now contains
complementary livestock veterinary products in beef, swine and poultry
production, as well as complementary companion animal veterinary
products and a redefined equine portfolio.
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc, is a world leader
in discovering and developing innovative animal prescription medicines
and vaccines, investing an estimated $300 million annually. For more
information on how Pfizer works to ensure a safe, sustainable global
food supply with healthy livestock, or how Pfizer helps companion
animals to live longer, healthier lives, visit animalhealth.pfizer.com.
For media & contact enquiries:
Maida Talhami 02-9850 3578
maida.talhami@pfizer.com